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Abstract
Background: Malaria is an old life-threatening parasitic disease that is still affecting many people, mainly children
living in sub-Saharan Africa. Availability of effective antimalarial drugs played a significant role in the treatment and
control of malaria. However, recent information on the emergence of P. falciparum parasites resistant to one of the
artemisinin-based combination therapies suggests the need for discovery of new drug molecules. Therefore, this
study aimed to evaluate the antiplasmodial activity of extracts, fractions and isolated compound from medicinal
plants traditionally used in the treatment of malaria in Tanzania.
Methods: Dry powdered plant materials were extracted by cold macerations using different solvents. Norcaesalpin
D was isolated by column chromatography from dichloromethane root extract of Caesalpinia bonducella and its
structure was assigned based on the spectral data. Crude extracts, fractions and isolated compound were evaluated
for antiplasmodial activity against chloroquine-sensitive P. falciparum (3D7), chloroquine-resistant P. falciparum
(Dd2, K1) and artemisinin-resistant P. falciparum (IPC 5202 Battambang, IPC 4912 Mondolkiri) strains using the
parasite lactate dehydrogenase assay.
Results: The results indicated that extracts of Erythrina schliebenii, Holarrhena pubescens, Dissotis melleri and C.
bonducella exhibited antiplasmodial activity against Dd2 parasites. Ethanolic root extract of E. schliebenii had an IC50
of 1.87 μg/mL while methanolic and ethanolic root extracts of H. pubescens exhibited an IC50 = 2.05 μg/mL and
IC50 = 2.43 μg/mL, respectively. Fractions from H. pubescens and C. bonducella roots were found to be highly active
against K1, Dd2 and artemisinin-resistant parasites. Norcaesalpin D from C. bonducella root extract was active with
IC50 of 0.98, 1.85 and 2.13 μg/mL against 3D7, Dd2 and IPC 4912-Mondolkiri parasites, respectively.
Conclusions: Antiplasmodial activity of norcaesalpin D and extracts of E. schliebenii, H. pubescens, D. melleri and C.
bonducella reported in this study requires further attention for the discovery of antimalarial lead compounds for
future drug development.
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Background
Malaria is an old mosquito borne disease which is still a
public health concern particularly in Africa [1]. Globally,
about 214 million people were recorded to suffer from
malaria in 2015 of which majority are found in sub-
Saharan Africa [2].
Efforts to control malaria have mainly depended on
the availability of effective antimalarial drugs and insecti-
cides to reduce both infections and transmission [3]. Use
of insecticide-treated bed nets (INTs), indoor residual
spraying (IRs), chemoprophylaxis in pregnant mothers
and increased access to effective antimalarial drugs have
significantly reduced morbidity and mortality, especially,
in malaria endemic areas [4]. However, these achieve-
ments are undermined by the existence of malaria para-
sites and mosquitoes which are resistant to antimalarial
drugs and pesticides, respectively [5].
In the early 2000s P. falciparum parasites resistant to
mefloquine, chloroquine, quinine, proguanil, atovaquone
and sulphadoxine-pyrimethamine, but not, artemisinins
were reported [6]. The WHO responded by restricting
artemisinin monotherapies and recommended use of
artemisinin-based combination therapies, ACTs [7] in
which the artemisinins are combined with long acting
drugs. Subsequently, increased access to the ACTs has
contributed significantly to reducing both infections and
malaria-related deaths, especially in sub-Saharan Africa
where the transmission is high [8]. Despite this positive
outcome, a recent report from South East Asia revealed
that P. falciparum parasites resistant to artemisinin have
now been identified in Myanmar, Cambodia, Thailand,
Viet Nam and Lao People’s Democratic Republic [9]. Re-
cently clinical failure to dihydroartemisinin-piperaquine
combination therapy was reported [10], suggesting that
the problem is increasing and thus there is need for
development of new drugs. To address this challenge,
researches which will identify new chemical compounds
with antimalarial properties are continuously needed.
Studying medicinal plants used in traditional medicine
for the treatment of malaria is among the many ap-
proaches used to identify new compounds with antimal-
arial properties [11]. Therefore, this paper reports the
antiplasmodial activity of extracts, fractions and one
compound from medicinal plants traditionally used for
the treatment of malaria in Tanzania.
Methods
Malaria parasites
Chloroquine-sensitive P. falciparum (3D7), chloroquine-
resistant P. falciparum (Dd2 and K1) and artemisinin-
resistant P. falciparum (IPC-5202 Battambang-Cambodia
2011 and IPC-4912 Mondolkiri-Cambodia 2011) strains
were used. All parasites were obtained from BEI-resources
(MR4/ATCC® Manassas, VA, USA).
Chemicals and reagents
Silica gel (230–400 mesh, 60 Å; Sigma, Steinheim,
Germany), dichloromethane (Carlo erba®, Val-de-Reuil,
France), ethyl acetate (Carlo erba®), ethanol (Carlo erba®),
methanol (Carlo erba®), dimethyl sulfoxide (Carlo erba®),
thin layer chromatography (TLC) plates (60 F254, Merck,
Darmstadt, Germany), Albumax II (GIBCO™, Invitrogen,
USA), RPMI-1640 (Sigma®), Foetal Bovine Serum (FBS,
BioWhittaker®, Verviers, Belgium), were used. All chemi-
cals and other materials used in this study were purchased
through local suppliers in Tanzania and in Cameroon, and
directly from SIGMA (Sigma®, Steinheim, Germany).
Collection and extraction of plant materials
Previous studies indicate that decoctions of E. schliebenii
roots and stem bark, H. pubescens roots, C. bonducella
roots and leaves, and decoction of D. melleri aerial parts
are used in traditional medicine for the treatment of mal-
aria [12–14]. Dissotis melleri Hook.f (Melastomataceae,
voucher No. RN 55) aerial parts were collected from Buzi
Kishura village in Kagera region and Caesalpinia bondu-
cella (L.) Flem (Caesalpiniacea, Voucher no. RN 93) roots
were collected from Gezaulole village in Dar es Salaam re-
gion, Tanzania. Holarrhena pubescens Huch-Ham (Apocy-
naceae, voucher No. 4665) roots and Erythrina schliebenii
Harms (Fabaceae, voucher No. 4661) stem bark and roots
were collected from Mchakama village in Lindi region,
Tanzania. The plants were identified by a botanist, Mr.
Selemani Haji, and the voucher specimens are deposited
in the Herbarium of the Institute of Traditional Medicine,
Muhimbili University of Health and Allied Sciences.
Dry powdered plant materials were extracted by cold
maceration using 80% ethanol, methanol, dichlorometh-
ane, or water. The crude extracts were dried in vacuo at
50 °C. Aqueous extracts were dried by freeze-drying and
the dry extracts were kept at −20 °C.
Fractionation of root extract of H. pubescens
Methanolic root extract of H. pubescens and dichloro-
methane root extract of C. bonducella were selected for
fractionation after showing both in vitro antiplasmodial
activity reported in this study and in vivo antimalarial
activity reported in our previous study [15]. The metha-
nolic root extract of H. pubescens was fractionated by
column chromatography with silica gel as the stationary
phase. The column was eluted by solvents of increasing
polarity starting with petroleum ether (100%). The polar-
ity of eluting solvent was increased using a step gradient
of ethyl acetate in petroleum ether in the following ratios:
ethyl acetate/petroleum ether (1:9), ethyl acetate/petrol-
eum ether (1:4), ethyl acetate/petroleum ether (2:3); ethyl
acetate/petroleum ether (1:1), ethyl acetate/petroleum
ether (7:3); ethyl acetate/petroleum ether (4:1), ethyl acet-
ate (100%) and finally eluted with methanol (100%). After
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analysis by thin layer chromatography (TLC), similar frac-
tions were combined to obtain 11 major fractions coded
as methanolic root extract of H. pubescens (HPRM-1
to 11). All fractions were air-dried and evaluated for
antiplasmodial activity against chloroquine-sensitive P.
falciparum (3D7), chloroquine-resistant P. falciparum
(Dd2 and K1) and artemisinin-resistant P. falciparum
(IPC-5202 and IPC-4912) parasites.
Isolation and characterization of pure compound from C.
bonducella root extract
General experimental procedure
Isolation of the compounds was done by column chro-
matography with silica gel as the stationary phase and
further purified by size exclusion column chromatog-
raphy using Sephadex® LH-20. Separation was monitored
by TLC in aluminium plates pre-coated with silica gel
and spots were visualized under UV light (254 nm) and
after spraying with vanillin plus heat [16]. 1H, 13C,
COSY, HSQC, HMBC and NOESY spectral data were
recorded on a Bruker Avance (600 MHz) NMR spec-
trometer in CD2Cl2 solvent with the residual solvent
signal (1H: 5.31, 13C: 53.7 ppm) as internal standard. EI-
MS spectrum was recorded on GC-MS TRACE DSQII
single quadruple mass spectrometer.
Extraction, fractionation, isolation and characterization of
compound
The dry-powdered roots of C. bonducella (1.7 Kg) were
macerated twice in dichloromethane for 24 h at room
temperature. The extract was dried in vacuo to give
46.3 g, out of which 40 g were fractionated in silica gel
column chromatography and eluted by solvents of in-
creasing polarity starting with 2.5 L of 100% petroleum
ether (yield 1.7 g) followed by 2.0 L of 1:1 petroleum
ether/dichloromethane (yield 6.5 g), 2.5 L of 100%
dichloromethane (yield 12.0 g), 2.5 L of 1:1 dichlro-
methane/ethyl acetate (yield 16.7 g) and 0.8 L of 100%
ethyl acetate (yield 1.0 g). All fractions were screened for
in vivo antimalarial activity against P. berghei ANKA
parasites at a dose of 200 mg/kg/day for a total of four
daily doses given orally. Among the tested fractions, 1:1
dichloromethane/ethyl acetate fraction showed highest
in vivo activity and therefore was selected for further
fractionation and isolation of active compounds. About
16.0 g of 1:1 dichloromethane/ethyl acetate fraction was
chromatographed in a silica gel column and eluted by
solvents of increasing polarity starting with 1:1 petrol-
eum ether/dichloromethane, then 1:4 petroleum ether/
dichloromethane, 100% dichloromethane and 9:1 dichlo-
romethane/ethyl acetate. Fraction number 12 obtained
from 9:1 dichloromethane/ethyl acetate showed some
crystals and this fraction was further purified by sepha-
dex column eluted by 100% ethyl acetate to produce 12
sub-fractions in which sub-fraction number 3 was found
to be white amorphous solid pure compound.
In vitro antiplasmodial activity
Chloroquine-sensitive P. falciparum (3D7), chloroquine-
resistant P. falciparum (Dd2 and K1) and artemisinin-
resistant P. falciparum (IPC 5202 Battambang-Cambodia
2011 and IPC 4912 Mondolkiri- Cambodia 2011) strains
were cultured in vitro according to the method of Trager
and Jensen [17]. Parasites were grown in uninfected O+
human red blood cells as host cells and maintained in
RPMI-1640 culture medium supplemented with NaHCO3
(2 mg/mL), hypoxanthine (10 μg/mL), glucose (2 mg/mL),
albumax II (1%) and gentamicin (10 μg/mL). The parasite
cultures were incubated at 37 °C in 5% CO2, 5% O2 and
90% N2. All solutions were filter-sterilized by 0.22 μm
syringe-adapted filters (Corning®, NY, USA).
In vitro antimalarial activity of extracts, fractions and
norcaesalpin D isolated from C. bonducella roots was
assessed by parasite lactate dehydrogenase (pLDH) assay
[18]. Non-synchronized 1% parasitized red blood cells
(pRBCs, mostly rings and trophozoites) at 2% haemato-
crit (hct) in 96 well microtiter plates (Costar®, Corning,
NY, USA) were incubated with different concentrations
of extract, fractions or norcaesalpin D. Quinine was used
as a standard drug. Each concentration was tested in
triplicate and each experiment was done twice. Wells
with only 1% pRBCs at 2% hct without extract, fraction
or drug were included as negative controls (100% para-
site growth) while wells with uninfected red blood cells
only at 2% hct served as blank controls. Parasite cultures
with extracts, fractions or compound were maintained for
48 h at 37 °C in 5% CO2, 5% O2, and 90% N2. After 48 h of
incubation, the plates were frozen overnight at −20 °C and
antimalarial activity was determined by pLDH assay
performed as described previously [19]. Concentra-
tions inhibiting 50 % of the parasite growth (IC50)
were determined by HN-NonLin V1.1, 2002 software
(http://www.meduniwien.ac.at/user/harald.noedl/malaria/
software.html) (Noedl H, 2002. Armed Forces Research
Institute for Medical Sciences, Bangkok, Thailand).
Cytotoxicity
Cytotoxicity was evaluated on LLC-MK2 monkey kidney
epithelial cells. Cells were grown in culture medium
prepared from solid RPMI-1640 with L-glutamine and
25 mM HEPES (Sigma®, Steinheim, Germany). The
medium was supplemented with NaHCO3 (2 mg/mL),
hypoxanthine (10 μg/mL), glucose (11.1 mM), 10% FBS
(BioWhittaker®, Verviers, Belgium) and gentamicin
(5 μg/mL). Adherent cells detached by trypsin-EDTA
treatment were distributed into 96 well microtiter plates
at 10,000 cells in 100 μL per well. The cells were incu-
bated for 48 h to allow them to attach before adding the
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extracts. After 48 h, the medium was removed com-
pletely from each well, and 100 μL of fresh culture
medium was then added. Thereafter, 100 μL of crude
extracts (400 μg/mL) were added in row H and then
serially diluted two fold to give concentrations ranging
from 200 to 3.125 μg/mL. Cells in row A served as con-
trols without drug (100% growth). The cells with or
without extracts/fractions/compound were incubated at
37 °C in atmosphere of 5% CO2 air for 72 h before de-
termining their viability. Each concentration was tested
in triplicate and each experiment was done twice. Cell
viability was determined by MTT assay and cytotoxic
activity was determined according to a method used in
our previous study [20]. Gleevec® (Imatinib) was used as
a cytotoxic drug. Selectivity index (SI) corresponding to
the ratio between cytotoxic activity and antiplasmodial
activity was calculated as follows: SI (Plasmodium) = CC50
(LLC-MK2)/ IC50 (P. falciparum).
Results
Structure elucidation of Norcaesalpin D
Norcaesalpin D (Fig. 1) was isolated as a white amorph-
ous solid pure compound from the dichloromethane
root extract of C. bonducella. The EI-MS gave molecular
ion peak [M+] at m/z 346 consistent with the molecular
formula C20H26O5. The
1H–NMR revealed twenty five
protons including methyl doublet at δ 0.87, two methyl
singlets at δ 1.15 and at δ 3.65 (methoxy protons) to-
gether with two olefinic protons of a 2,3-disubstituted
furan ring at δ 6.59 (dd, J = 2.0, 0.4) and at δ 7.32
(d, J = 1.8). The 13C–NMR showed signals for twenty
carbons of which two were carbonyl carbons at δ 195.9 cor-
responding to C-14 ketone group and at δ 177.2 represent-
ing C-19 carbonyl ester. One signal for methoxy carbon at
δ 51.7 was observed. In addition to that, four signals for
olefinic carbons at δ 167.1 (C-12), δ 119.8 (C-13), δ 106.4
(C-15) and δ 143.1 (C-16) of furan ring attached to another
ring were observed. The significantly downfield chemical
shift value of C-12 was attributed to resonance of a conju-
gated carbonyl residue at C-14. Its structure (Fig. 1) was
assigned (Table 1) based on 1H, 13C, COSY, HSQC, HMBC
and NOESY spectral data. The compound was identified as
norcaesalpin D, previously isolated from the dichlorometh-
ane root extract of C. bonducella and its structure was con-
firmed by comparing with previously reported data [21];
however no antiplasmodial activity was reported before.
In vitro antiplasmodial and cytotoxic activity of
norcaesalpin D and extracts of four plants
Antiplasmodial activity of extracts of E. schliebenii, H.
pubescens, D. melleri and C. bonducella was determined
Fig. 1 Structure of Norcaesalpin D (methyl-12,16-epoxy-5α-
hydroxynorcasa-12,15-dien-14-one-19-carboxylate)
Table 1 1H–NMR and 13C–NMR (δ values; J values in Hz) data
for Norcaesalpin D
Position Observed value
(600 MHz in CD2Cl2)
Reported value by Roach
et al., 2007 (500 MHz
in CDCl3)
δC mult δH, mult (J in Hz) δC δH, mult (J in Hz)














6 28.2 1.84, ddd (14.9, 4.2, 2.6)
2.37, td (14.6, 4.8)
27.9 1.88, m
2.40, m




8 44.3 2.31,td (11.9, 4.8) 44.2 2.33, m
9 44.7 2.59, m 44.5 2.62, m
10 41.9 41.7






15 106.4 6.59, dd (2.0, 0.4) 106.5 6.64, d (2.0)
16 143.1 7.32, d (1.8) 142.2 7.30, d (2.0)
17 - -
18 23.7 1.15, s 23.7 1.19, s
19 177.2 177.2
20 15.1 0.87, d (0.6) 15.1 0.89, s
19-OMe 51.7 3.65, s 51.7 3.69, s
Assignments were based on COSY, HSQC and HMBC experiments
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against chloroquine-resistant P. falciparum Dd2 strains.
The results showed that all extracts were active with
IC50 < 25 μg/mL. Among the extracts investigated, root
extracts of E. schliebenii and H. pubescens possessed the
highest antiplasmodial activity with IC50 < 5 μg/mL. The
ethanolic root extract of E. schliebenii had an IC50 of
1.87 μg/mL while methanolic and ethanolic root extracts
of H. pubescens exhibited an IC50 = 2.05 μg/mL and
IC50 = 2.43 μg/mL, respectively. The aqueous extract of E.
schliebenii stem bark (IC50 = 7.04 μg/mL) and ethanolic
extract of D. melleri (IC50 = 8.23 μg/mL) demonstrated
promising antiplasmodial activity while dichloromethane
root extract of C. bonducella exhibited moderate antiplas-
modial activity with IC50 of 24.05 μg/mL (Table 2). In
addition, results of cytotoxicity study revealed that all
extracts were non-toxic to mammalian (LLC-MK2) cells
with CC50 > 30 μg/mL cut-off point (Table 2).
Two fractions from the methanolic root extract of
H. pubescens coded as HPRM-5 and 7 were evalu-
ated for antiplasmodial activity against chloroquine-
sensitive P. falciparum (3D7), chloroquine-resistant (K1)
and artemisinin-resistant strains (IPC 5202 Battambang
and IPC 4912 Mondolkiri). Although the results revealed
both fractions were active, HPRM-7 had high activity
against all P. falciparum strains tested. Fraction HPRM-5
obtained from 40% ethyl acetate/petroleum ether column
fractions inhibited the growth of P. falciparum 3D7
(IC50 = 3.14 μg/mL), K1 (IC50 = 5.23 μg/mL), IPC 5202
Battambang (IC50 = 11.46 μg/mL) and IPC 4912 Mon-
dolkiri (IC50 = 8.61 μg/mL). Similarly, fraction HPRM-7
from 70% ethyl acetate/petroleum ether column frac-
tions exhibited strong antiplasmodial activity against
3D7 with IC50 = 1.2 μg/mL, K1 (IC50 = 2.18 μg/mL),
and IPC 5202 Battambang IC50 = 2.52 μg/mL) and
promising activity against IPC 4912 Mondolkiri with
IC50 = 5.95 μg/mL (Table 3).
The 1:1 dichloromethane/ethyl acetate column fraction
and its sub-fraction (sub-fraction 1) from dichloromethane
crude extract of C. bonducella root exhibited high to
moderate antiplasmodial activity against P. falciparum 3D7,
P. falciparum Dd2 and P. falciparum IPC 4912 Mondolkiri.
Generally, the activity of these fractions increased with
purity of the fraction (Table 4). Norcaesalpin D isolated
from sub-fraction 1 was active with IC50 of 0.98, 1.85
and 2.13 μg/mL against chloroquine-sensitive (3D7),
chloroquine-resistant (Dd2) and artemisinin-resistant
(IPC 4912 Mondolkiri) P. falciparum parasites, respect-
ively. Cytotoxicity evaluation showed that norcaesalpin D
is non-toxic to mammalian cells with CC50 > 200 μg/mL
(Table 4).
Discussion
This study aimed to assess the antiplasmodial activity of
extracts of E. schliebenii roots and stem bark, H. pubescens
roots, D. melleri aerial parts and C. bonducella roots. Also,
the study assessed the antiplasmodial activity of fractions
and norcaesalpin D isolated from C. bonducella roots.
The results indicate that extracts, fractions and norcae-
salpin D possess in vitro antiplasmodial activity against
chloroquine-sensitive (3D7), chloroquine-resistant (Dd2
and K1) and artemisinin-resistant P. falciparum (IPC 5202
Battambang and IPC 4912 Mondolkiri) parasites. Accord-
ing to Jonville et al., [22], antiplasmodial activity of
extracts and fractions can be classified as high activity
(IC50 < 5 μg/mL), promising activity (IC50 = 5–15 μg/mL),
moderate activity (IC50 = 15–50 μg/mL) and inactive
(IC50 = >50 μg/mL). Based on this, all crude extracts
of E. schliebenii, H. pubescens, D. melleri and C.
bonducella were active against chloroquine-resistant
P. falciparum Dd2; however, root extracts of E. schlie-
benii and H. pubescens exhibited the highest antiplas-
modial activity with IC50 < 5 μg/mL. The aqueous extract
of E. schliebenii stem bark, ethanolic extract of D. melleri,
and dichloromethane root extract of C. bonducella
showed promising to moderate antiplasmodial activity
with IC50 < 25 μg/mL (Table 2). In addition, cytotoxicity
study of the extracts revealed that all extracts were
non-toxic to mammalian (LLC-MK2) cells with
Table 2 In vitro anti-plasmodial activity and cytotoxicity of plant extracts
Plant (Family) Part (extract) Antiplasmodial activity Cytotoxicity Selectivity
index (SI)IC50 on Dd2
(μg/mL ± SD)
CC50 on LLC-MK2 (μg/mL ± SD)
Erythrina schliebenii (Fabaceae) R (80% Ethanol) 1.87 ± 0.44 >200 >109
SB (H2O) 7.04 ± 0.72 >200 >28.4
Holarrhena pubescens (Apocynaceae) R (80% Ethanol) 2.43 ± 0.15 >200 >82.3
R (Methanol) 2.05 ± 0.56 >200 >97.6
Dissotis melleri Hook.f (Melastomataceae) AP (80% Ethanol) 8.23 ± 1.32 83.33 ± 3.31 10.1
Caesalpinia bonducella (Caesalpinaceae) R (Dichloromethane) 24.05 >200 >8.3
QN 0.06 ± 0.01
Gleevec® (Imatinib) 19.43 ± 2.87
R root, SB stem bark, AP aerial parts (stem + leaves), QN quinine
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CC50 > 80 μg/mL (Table 2). These findings against
chloroquine-resistant P. falciparum parasites suggest
that E. schliebenii, H. pubescens, D. melleri and C. bon-
ducella can be potential sources for the isolation of safe
and effective antimalarial lead compounds.
In our previous study we reported that extracts of E.
schliebenii stem bark, H. pubescens roots and C. bondu-
cella roots had in vivo antimalarial activity against P.
berghei ANKA in mice [15]. In this study we found that
extracts and fractions of these plants exhibited strong to
moderate antiplasmodial activity against multi-drug re-
sistant P. falciparum Dd2 malaria parasites. These find-
ings therefore provide more scientific evidence on the
antimalarial properties and the use of these plants in
traditional medicines for the treatment of malaria. Further-
more, two column fractions from the active extract of H.
pubescens roots showed high antiplasmodial activity
against 3D7, K1, IPC 5202 Battambang and IPC 4912
Mondolkiri parasites. Fraction HPRM-7 from 70% ethyl
acetate/petroleum ether column fractions exhibited strong
antiplasmodial activity against 3D7 (IC50 = 1.2 μg/mL), K1
(IC50 = 2.18 μg/mL), and IPC 5202 Battambang
IC50 = 2.52 μg/mL) and promising activity against IPC
4912 Mondolkiri (IC50 = 5.95 μg/mL) as presented in
Table 3. Artemisinin-based combination therapies (ACTs)
are currently the only effective drugs available for the
treatment of malaria [23]. However, recent report on the
emergence of P. falciparum parasites resistant to
dihydroartemisinin-piperaquine [10] which is one of the
highly effective ACTs is an indication that new molecules
with antimalarial properties need to be discovered. The
antiplasmodial activity observed in some of the extracts
and fractions against artemisinin-resistant P. falciparum
suggest that medicinal plants can still offer more antimal-
arial lead compounds for future drug development.
While the antiplasmodial properties of extracts of E.
schliebenii, H. pubescens and C. bonducella were re-
ported earlier [13, 14, 24], the antiplasmodial activity of
D. melleri is reported for the first time by this study.
Ethanolic extract of D. melleri aerial parts showed prom-
ising antiplasmodial activity against P. falciparum Dd2
parasites in vitro with IC50 = 8.23 μg/mL. A previous
study showed that stem extracts of Dissotis brazzae
Cogn exhibited antiplasmodial activity against P. falcip-
arum chloroquine-resistant (ENT 36 strain) with
IC50 = 6.4 μg/mL. Preliminary phytochemical analysis of
the extracts of D. brazzae revealed the presence of alka-
loids, coumarins, saponins, triterpenoids, steroids, and
tannins which are associated with the antiplasmodial
activity of this plant [25]. The antiplasmodial activity of
D. melleri could therefore be an indication that the
genus Dissotis can be a potential source for the isolation
of compounds with antimalarial activity.
Dichloromethane crude extract of C. bonducella root
was reported earlier to have dose-dependent in vivo
antimalarial activity in mice [15]. The results from this
study indicate that dichloromethane crude extract of C.
bonducella root exhibited low in vitro antiplasmodial
activity (Table 2). The low in vitro antiplasmodial activ-
ity observed in this study can be explained by the poor
solubility of the extracts in aqueous medium. This
extract dissolved completely in dimethylsulfoxide but
Table 3 In vitro antiplasmodial activity of fractions from H. pubescens methanolic root extract
Fraction Antiplasmodial activity
IC50 ± SD (μg/mL)
Cytotoxicity
CC50 ± SD (μg/mL)




Fraction HPRM- 5 3.14 ± 0.18 5.23 ± 0.03 11.46 ± 0.2 8.61 ± 0.97 >200
Fraction HPRM- 7 1.20 ± 0.35 2.18 ± 0.95 2.52 ± 1.8 5.95 ± 2.79 >200
QN 0.052 ± 0.01 0.060 ± 0.01 0.074 ± 0.0 0.068 ± 0.005 >200
HPRM-5 40% ethyl acetate/petroleum ether column fraction of H. pubescens methanolic root extract, HPRM-7 70% ethyl acetate/petroleum ether column fraction
of H. pubescens methanolic root extract, QN quinine
Table 4 Anti-plasmodial activity of Norcaesalpin D and fractions from C. bonducella roots
Fraction/Compound Antiplasmodial activity
IC50 ± SD (μg/mL)
Cytotoxicity CC50 ± SD (μg/mL) Selectivity index
(SI) against IPC-4912
3D7 Dd2 IPC 4912 Mondolkiri Cambodia 2011 CC50 on LLC-MK2 (μg/mL ± SD)
1:1 DCM/EtoAC fraction 4.08 ± 2.87 9.33 ± 2.09 2.99 ± 4.84 76.09 ± 8.44 25.4
Sub-fraction 1 (Semi-pure) 3.06 ± 0.80 2.26 ± 0.97 5.12 ± 1.0 > 200 >39.1









QN 0.052 ± 0.01 0.06 ± 0.01 0.068 ± 0.005
1:1 DCM/EtoAC =1:1 dichloromethane/ethyl acetate fraction of dichloromethane root extract of C. bonducella; Sub-fraction 1 = column fraction of 1:1 DCM/EtoAC
fraction; Norcaesalpin D isolated from sub-fraction1
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precipitated on addition of aqueous solvents. However,
dichloromethane/ethyl acetate (1:1) column fraction and
its sub-fraction 1 from dichloromethane root extract of C.
bonducella showed high in vitro antiplasmodial activity
against P. falciparum 3D7, Dd2 and IPC 4912 Mondolkiri
strains (Table 4). Norcaesalpin D (Fig. 1) is a 17-
norcassane furanoditerpene isolated from the sub-
fraction 1. This compound revealed strong antiplas-
modial activity with IC50 of 0.98, 1.85 and 2.13 μg/mL
against P. falciparum 3D7, Dd2 and IPC 4912 Mondolkiri
parasites, respectively (Table 4). The antiplasmodial
activity of this compound is reported for the first time by
this study. A previous study indicated that this compound
together with 17-O-Demethylbonducellpin C; 7-Dehydr
oxycaesaldekarin I; Caesaldekarin C, Caesaldekarin F,
Caesaldekarin J and Caesalpin F were isolated from di-
chloromethane root extract of C. bonducella but no anti-
plasmodial activity was reported. Caesaldekarin C and
Caesaldekarin F were reported to have cytotoxic activity
against a number of cancer cell lines [21]. In addition,
cassane-type diterpenoid compounds from Caesalpinia
have been reported to have antiplasmodial properties.
Norcaesalpinin E from the seeds of C. crista revealed high
antiplasmodial activity (IC50 = 0.09 μM) against P. falcip-
arum FCR – 3/A2 [26]. Thus, the in vitro antiplasmodial
activity of norcaesalpin D observed in this study confirms
the antimalarial activity of the C. bonducella root extract.
Further evaluation of the compound for in vivo antimalar-
ial activity is suggested.
Conclusions
Antiplasmodial activity of the extracts of E. schliebenii,
H. pubescens, D. melleri and C. bonducella reported in
this study provide scientific evidence supporting their
use for the treatment of malaria. Antiplasmodial activity
demonstrated by norcaesalpin D against artemisinin-
resistant P. falciparum parasites requires further atten-
tion for the discovery of antimalarial lead compounds
for future use.
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